Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting. Learn More
Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting. Learn More
Dr. Boris Pasche, MD, PhD explains how the TheraBionic P1 medical device works to treat cancer. The TheraBionic P1 device is currently FDA approved for treatment of adult patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, for...
Liver cancer is one of the most difficult solid tumors to treat and is responsible for one-third of cancer-related deaths worldwide. In particular, the quest for effective therapeutic strategies for hepatocellular carcinoma, which often arises from a chronic...
Metabolic syndrome (MetS) elevates cancer risk. However, a single MetS assessment does not fully reveal the long-term association with cancer. Inflammation, alongside MetS, could synergistically expedite both the onset and advancement of cancer. This study aims to...
Cholangiocarcinoma (CCA) manifests as a complex interplay of genetic and environmental factors, necessitating personalized approaches. This review covers the various causes, risk factors, and molecular aspects of CCA in oncology. It explores current diagnostic methods...
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival...
TriSalus Life Sciences (NASDAQ:TLSI) is addressing the mechanical and biologic barriers, such as high intratumoral pressure, within the tumor microenvironment (TME) that make it challenging to successfully treat liver and pancreatic tumors. Learn...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients with locally...
Medical experts, Dr. Joan Culpepper-Morgan and Dr. Susanne G. Warner, touch upon treatment advancements for patients presenting with hepatocelluar carcinoma (HCC). In this article, both doctors cover a range of therapies that can be tailored and personalized to the...
In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%. Up to 80% of people with this type of HCC experience disease recurrence, at which point they are...
Hepatoblastoma is a very rare liver cancer (malignant tumor) that affects babies and toddlers ages 1 to 3. It’s treated with surgery. Rarely, hepatoblastoma may spread outside children’s livers. Hepatoblastoma may be “cured” with chemotherapy to shrink cancerous...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in...
In this webinar, Steven C. Katz, M.D., FACS, Chief Medical Officer at TriSalus Life Sciences, leads a review of the Pressure-Enabled Regional Immuno-Oncology (PERIO-02) clinical trial for adults with intrahepatic cholangiocarcinoma and hepatocellular carcinoma, the...
Dr. Sapna Patel from MD Anderson presented early data from the Pressure-Enabled Regional Immuno-Oncology-01 (PERIO-01) clinical trial at SITC’s Tumor Microenvironment: A Holistic Approach Workshop. Early findings suggest Pressure-Enabled Drug Delivery™ enabled SD-101...
A Cure in Sight, in collaboration with the Ocular Melanoma Foundation, hosted an educational webinar on the Pressure-Enabled Regional Immuno-Oncology-01 (PERIO-01) clinical trial for uveal melanoma with liver metastases. This webinar featured insights from Drs....
Primary liver cancer death rates vary by region, and much is still to be done in the area of health equity. Primary liver cancer is a leading cause of cancer-related illness and death worldwide. It is the sixth most-common cancer and the third most-common cause of...
Health related quality of life (HRQOL) for patients undergoing treatment for unresectable hepatocellular carcinoma is an important therapeutic consideration. The evidence of HRQOL benefits in clinically relevant domains support the use of lenvatinib compared with...
Hepatocellular carcinoma is a common cancer worldwide and a leading cause of cancer-related death. Although early-stage disease may be curable by resection, liver transplantation, or ablation, most patients present with unresectable disease and have a poor prognosis....